To Compare Efficacy and Safety of CMAB007 and Xolair ® in Patients With Chronic Spontaneous Urticaria
Conditions: Chronic Spontaneous Urticaria Interventions: Drug: CMAB007; Drug: Xolair Sponsors: Taizhou Mabtech Pharmaceutical Co.,Ltd Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 15, 2024 Category: Research Source Type: clinical trials
A Clinical Study of Omalizumab in the Treatment of Allergic Asthma(ESSENCE)
Conditions: Moderate to Severe Allergic Asthma Interventions: Drug: IgE monoclonal antibody Sponsors: The First Affiliated Hospital with Nanjing Medical University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 4, 2024 Category: Research Source Type: clinical trials
Omalizumab in Severe Asthmatics With Food Allergy
Conditions: Food; Allergy, Anaphylactic Shock; Asthma in Children Interventions: Biological: Omalizumab Sponsors: Bambino Ges ù Hospital and Research Institute Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 18, 2024 Category: Research Source Type: clinical trials
Antibody Reduces Allergic Reactions to Multiple Foods in NIH Clinical Trial
February 25, 2024 -- A 16-week course of a monoclonal antibody, omalizumab, increased the amount of peanut, tree nuts, egg, milk and wheat that multi-food allergic children as young as 1 year could consume without an allergic reaction in a... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - February 25, 2024 Category: Pharmaceuticals Source Type: clinical trials
Efficacy and Safety of LP-003 in Patients With CSU Who Remain Symptomatic Despite Antihistamine (H1) Treatment
Conditions: Chronic Spontaneous Urticaria Interventions: Biological: LP-003; Biological: Placebo; Biological: Omalizumab Sponsors: Longbio Pharma Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 29, 2024 Category: Research Source Type: clinical trials
E-B-FAHF-2, Multi OIT and Xolair for Food Allergy
Conditions: Food Allergy Interventions: Drug: Drug: Chinese Herbal Medication; Drug: Drug: Placebo; Drug: Drug: Omalizumab Sponsors: New York Medical College; Icahn School of Medicine at Mount Sinai Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 27, 2023 Category: Research Source Type: clinical trials
A Real-world Study to Assess Safety and Effectiveness of Xolair ® in Pediatric Chronic Spontaneous Urticaria in China
Condition: Chronic Spontaneous Urticaria Intervention: Other: Xolair Sponsor: Novartis Pharmaceuticals Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 26, 2023 Category: Research Source Type: clinical trials
A Real-world Study to Assess Safety and Effectiveness of Xolair ® in Pediatric Chronic Spontaneous Urticaria in China
Conditions: Chronic Spontaneous Urticaria Interventions: Other: Xolair Sponsors: Novartis Pharmaceuticals Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 26, 2023 Category: Research Source Type: clinical trials
52 Weeks Double-blind, Double-dummy, Randomized Placebo-controlled Trial to Evaluate Safety, Efficacy and Tolerability of Remibrutinib in Comparison to Placebo With Omalizumab as Active Control in Adult Patients With CSU and Inadequate Response to H1-antihistamine.
Condition: Chronic Spontaneous Urticaria Interventions: Drug: Remibrutinib; Drug: Placebo to remibrutinib; Drug: Placebo to omalizumab; Drug: Omalizumab Sponsor: Novartis Pharmaceuticals Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 18, 2023 Category: Research Source Type: clinical trials
A Phase 3b Study to Assess the Efficacy, Safety, and Tolerability of Remibrutinib in Comparison to Placebo and With Omalizumab as Active Control in CSU Adult Patients.
Condition: Chronic Spontaneous Urticaria Interventions: Drug: Remibrutinib; Drug: Placebo to remibrutinib; Drug: Placebo to omalizumab; Drug: Omalizumab Sponsor: Novartis Pharmaceuticals Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 18, 2023 Category: Research Source Type: clinical trials
